The emergence of CRISPR-Cas systems has accelerated the development of gene editing
technologies, which are widely used in the life sciences. To improve the performance of …

Clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR associated
protein (Cas)-mediated gene disruption has revolutionized biomedical research as well as …

Base editors have substantial promise in basic research and as therapeutic agents for the
correction of pathogenic mutations. The development of adenine transversion editors has …

Although miniature CRISPR-Cas12f systems were recently developed, the editing efficacy
and targeting range of derived miniature cytosine and adenine base editors (miniCBEs and …

Base editors (BEs) empower the efficient installation of beneficial or corrective point
mutations in crop and human genomes. However, conventional BEs can induce …

Whole-brain genome editing to correct single-base mutations and reduce or reverse
behavioral changes in animal models of autism spectrum disorder (ASD) has not yet been …

Base editors (BEs) have opened new avenues for the treatment of genetic diseases.
However, advances in delivery approaches are needed to enable disease targeting of a …

Advancements in CRISPR technology, particularly the development of base editors,
revolutionize genetic variant research. When combined with model organisms like zebrafish …

Nme2Cas9 has been established as a genome editing platform with compact size, high
accuracy, and broad targeting range, including single-AAV-deliverable adenine base …

About 47% of pathogenic point mutations could be corrected by ABE-induced A· T-to-G· C
conversions. However, the applications of ABEs are still hindered by undesired editing …